

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

January 23, 2025

R. Kirk HuntsmanChairman of the Board and Chief Executive OfficerVivos Therapeutics, Inc.7921 Southpark Plaza, Suite 210Littleton, Colorado 80120

Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 Filed January 22, 2025 File No. 333-284399

Dear R. Kirk Huntsman:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Conlon Danberg at 202-551-4466 with any questions.

Sincerely,

Division of Corporation Finance Office of Industrial Applications and Services

cc: Lawrence A. Rosenbloom, Esq.